AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Ephrin-A5

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P52803

UPID:

EFNA5_HUMAN

Alternative names:

AL-1; EPH-related receptor tyrosine kinase ligand 7

Alternative UPACC:

P52803

Background:

Ephrin-A5, known alternatively as AL-1 and EPH-related receptor tyrosine kinase ligand 7, plays a pivotal role in neuronal, vascular, and epithelial development. It functions as a cell surface GPI-bound ligand for Eph receptors, facilitating crucial processes such as migration, repulsion, and adhesion through bidirectional signaling. Ephrin-A5's interaction with Eph receptors, including EPHA3 and EPHA2, influences cell-cell adhesion, cytoskeletal organization, lens transparency, axon fasciculation, and glucose-stimulated insulin secretion.

Therapeutic significance:

Understanding the role of Ephrin-A5 could open doors to potential therapeutic strategies, particularly in enhancing neuronal, vascular, and epithelial development, as well as in managing diabetes through the regulation of insulin secretion.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.